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Objectives: Carotid endarterectomy (CEA) remains the gold standard for treatment of carotid stenosis. With inevitable
comparisons of catheter-based therapy to all aspects of CEA, this study of a large contemporary series was undertaken to
evaluate the determinants of anatomic durability of CEA.
Methods: During the interval (1989 through 1999), 2,127 primary, isolated CEAs with selective patching (50.2%) were
performed in 1,853 patients (61.8% male, 36.1% symptomatic). End points included patient longevity and perioperative
morbidity as well as evidence of CEA anatomic durability as defined by duplex evaluation: CEA restenosis (moderate,
>50%, or greater recurrent stenosis), which included CEA anatomic failure (severe,>70%, restenosis/carotid occlusion).
The incidence of CEA recurrent stenosis was temporally assessed early (<2 years) and late (>2 years) after operation.
Clinical and surgical variables potentially associated with the study endpoints were analyzed by univariate and
multivariate methods.
Results: The perioperative stroke and death rate was 1.4% and the 2-year and 10-year survival was 88.1% and 44.9%,
respectively. Anatomic failure after CEA developed in 3.9% at 2 years and in 8.5% at 5 years; only 3.2% of CEA patients
underwent reoperation during a mean follow-up of 73.4 months. Early (<2 years) analysis revealed 12.2% restenosis,
whereas late (>2 years) results identified 9.8% progression of carotid stenosis and a 5.8% rate of anatomic failure.
Multivariate analysis determined elevated creatinine (odds ratio [OR], 1.719, P < .001) and female gender (OR, 1.564;
P < .02) correlated with early restenosis. Surgical patch closure and lipid-lowering drugs were protective for both early
restenosis, with ORs of 0.543 (P< .0.001) and 0.601 (P< .007) and early anatomic failure ORs of 0.469 (P< .02) and
0.517 (P < .03), respectively. Although only elevated serum cholesterol (OR, 1.009; P < .03) correlated with late
anatomic failure, only lipid-lowering drugs were protective for both late freedom from progression of disease (OR, 0.202;
P < .0002) or late CEA anatomic failure (OR, 0.128; P < .0003).
Conclusions: The association of female gender and elevated cholesterol with recurrent carotid stenosis is confirmed,
elevated creatinine is introduced as a risk factor, and surgical patch repair is protective for early CEA recurrent carotid
stenosis. The unique findings of the significant, beneficial effects of lipid-lowering drugs on both early and late CEA
anatomic durability and patient survival indicate that such therapy should be instituted in most patients after CEA.
(J Vasc Surg 2005;41:762-8.)Ample evidences supports carotid endarterectomy
(CEA) as the standard treatment for clinically significant
symptomatic and asymptomatic carotid stenosis. Level 1
evidence from prospective, randomized trials,1,2 including
the recently published Asymptomatic Carotid Surgery Trial
(ACST),3 has demonstrated that CEA significantly reduces
the incidence of stroke and death compared with best
medical treatment. With these and other studies delineat-
ing the natural history of severe carotid stenosis, a consen-
sus has emerged that perioperative surgical morbidity is the
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762major determinant for assessing the benefit of CEA over
best medical therapy.4 However, in view of the ultimate
goal of CEA—stroke prevention—an important additional
consideration is long-term anatomic durability and patient
outcome after CEA.
Despite reports of favorable anatomic durability of
CEA, the length of patient follow-up and the criteria se-
lected for defining recurrent stenosis have varied consider-
ably.5-8 It has been generally accepted that postoperative
stenosis development after CEA can be temporally catego-
rized into early restenosis (2 years) or late recurrent
stenosis (2 years). Although both temporal and pathol-
ogy overlap occurs, the general agreement is that early
restenosis is largely intimal hyperplasia, whereas lesions that
develop 2 years have more findings consistent with recur-
rent atherosclerosis.9,10 Studies have identified clinical and
surgical variables associated with this process in CEA pa-
tients, but the data are conflicting as to which factors are
important contributors for the development of recurrent
carotid stenosis.7,11-13
Recently, the alternative therapeutic approach of ca-
rotid artery stenting was reported to demonstrate compa-
rable short-term outcomes with CEA in a randomized
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these apparently equivalent periprocedural findings, the
comparison of the long-term durability of these reconstruc-
tions will assume greater importance.
Novel medical therapies have been reported to improve
the natural history of cardiovascular disease in patients with
diminished events, including better outcomes after vascular
interventions such as coronary stents.15-18 The present
study, therefore, carefully addresses the influence of a wide
range of clinical and surgical variables on the short-term
and long-term anatomic durability and patient survival of
primary CEA.
METHODS
Patient selection. The computerized databases and
medical records of the Massachusetts General Hospital
(retrospective), Vascular Surgery Registry, and operative
logs (prospective) were cross-referenced to identify 1,853
patients who underwent 2,127 consecutive primary CEA
procedures from January 1989 throughDecember 1999 by
surgeons in the Division of Vascular and Endovascular
Surgery. Only non-reoperative, isolated CEA were in-
cluded in the study. Excluded from analysis was a CEA
performed in conjunction with cardiac surgery or with any
additional procedure, such as a carotid bypass.
Patient clinical and laboratory parameters, operative
details, postoperative carotid noninvasive studies, and the
clinical course were recorded. The clinical criteria determi-
nation was made at the time of CEA, and their definitions
are:
● hypertension: taking antihypertensive medication,
consistent blood pressure 150 mm Hg systolic or
90 mm Hg diastolic;
● diabetes mellitus: receiving insulin, oral hypoglycemic
medication, or having two serum blood glucose values
150 mg/dL;
● coronary artery disease: history of myocardial infarc-
tion, congestive heart failure, coronary artery bypass
graft or intervention, symptoms of angina, or identifi-
cation by a positive stress test;
● chronic obstructive pulmonary disease: routine use of
inhalers or symptoms of lifestyle limiting dyspnea
Laboratory values used were those at the time of sur-
gery, except for a fasting lipid profile that was recorded
from the perioperative period (when available) and in the
follow-up period beyond the 2-year time frame.
Recurrent stenosis. The primary end point of the
study was postoperative recurrent carotid stenosis. The
severity of the recurrent carotid disease was quantitatively
based on duplex peak systolic velocity, internal carotid-to-
common carotid ratio (moderate, 2 to 4; severe, 4), and
end-diastolic velocity (moderate, 100cm/s; severe,
140cm/s). Postoperative surveillance of CEA was gener-
ally performed with a baseline within 2 months, and then
every 6 months for the first 2 years. Later studies were more
sporadic and related to the age of the patient, findings on
duplex scans, and physician preference.The duplex results were thus categorized into minimal
or no recurrent stenosis, moderate recurrent stenosis
(50% to 69%), severe recurrent stenosis (70% to 99%), or
occlusion. To better reflect clinical relevance, end points
were defined as (1) restenosis (development of a moderate
or greater stenosis) that included anatomic failure and (2)
anatomic failure (development of a severe recurrent steno-
sis or occlusion). From these results, patients were tempo-
rally divided into two groups for analysis: early (2 years)
and late (2 years).
Only the occurrence of carotid occlusion or reoperative
CEA during the early time period excluded such patients
from analysis during the subsequent late period because no
measurable change could be assessed. All other patients
were analyzed in the subsequent late time period irrespec-
tive of the anatomic category of their carotid artery. Be-
cause the anatomic category of the carotid artery could vary
between no to severe recurrent stenosis when entering the
late time period 2 years, analysis of this group of CEA
patients was conducted by evaluating for progression in the
extent of the recurrent stenosis and determining the occur-
rence of CEA anatomic failure, as previously defined.
Multiple variables were examined to determine their
effects on the development of recurrent stenosis. They were
divided into the three general categories of clinical factors,
surgical features, and lipid parameters. Patients taking lipid-
lowering drugs were identified in both the early and late
time period. Patients were classified as taking a hydroxym-
ethylglutaryl coenzyme A reductase inhibitor (statin), any
other cholesterol lowering drug, or both forms of medica-
tion.
Patient outcome. Secondary end points in the study
included 30-day perioperative complications and patient
longevity. For patients who lacked long-term follow-up,
outcome data were supplemented by direct telephone con-
tact with the patient (n  220, 11.8% of original group).
For patients who lacked recent clinical data and could not
be reached, the date and causes of death were requested
and, if available, procured from the National Death Index
in Bethesda, Md.
The protocols of this study were independently re-
viewed and approved by the institutional human study
committee. In addition, the review board of the National
Death Index in Bethesda, Md, approved the protocol for
release of the patient data.
Data analysis. The effect of variables on dichotomous
outcomes, early restenosis, early failure, late progression,
and late failure were determined using logistic regression.
Survival and progression of restenosis were assessed using
Kaplan-Meier estimates. The effects of dichotomous pre-
dictors were determined using the log-rank test. The asso-
ciation of variables was evaluated using the Fischer exact
test. The data set was based on the first operation for each
patient. To test for a synergy between statin and nonstatin
drugs, the two dichotomies and the interaction term were
included in logistic regression models. Calculations were
made with the open-source R statistical package. Data were
JOURNAL OF VASCULAR SURGERY
May 2005764 LaMuraglia et alpresented as averages  SD, and a P  .05 was considered
statistically significant.
RESULTS
During the study period 2,127 CEA operations per-
formed on 1,853 patients. Patients averaged 70.5  2.7
years of age, and theymanifestedmany of the comorbidities
present in patients with arteriosclerosis (Table I). Surgical
characteristics included 36.1% symptomatic patients, selec-
tive shunting (33.0%), and patching (50.2%) of the carotid
reconstruction (Table II). Perioperative complications
(5.5%) were identified with 13 deaths (6 involving strokes)
and 17 postoperative strokes (Table III).
Anatomic failure. The follow-up anatomic results of
all CEA are delineated by Kaplan-Meyer estimate in Fig 1.
Carotid duplex follow-up data were available in 84% of
CEA patients during the early time period and in 60% of
surviving, eligible CEA patients during the late follow-up.
To ensure completeness of CEA, residual stenosis was
measured at the first postoperative carotid duplex evalua-
tion, which was performed within 2months of surgery. The
rate of residual restenosis was 2.2% (1.3% mild and 0.9%
moderate), and these CEAwere included in the subsequent
analysis.
During a mean follow-up of 73.4 months, 57 patients
(3.2%) underwent reoperative CEA, 18 (32%) of whom
presented with ipsilateral neurologic symptoms. The inci-
dence of early restenosis was 12.2%, and included 3.8%
early anatomic failure. The anatomy of 9.8% CEAs had
progression of the stenosis in the late follow-up period,
whereas 5.8% progressed to anatomic failure. The incidence
Table I. Patient demographics
Number (%)
Patients 1,853
Age (years) 70.5  2.7
Male 1138 (61.8)
Hypertension 1457 (79.6)
Diabetes mellitus 447 (24.6)
Coronary artery disease 1009 (55.3)
Chronic obstructive pulmonary disease 243 (13.2)
Tobacco 1234 (67.5)
Former 898 (49.1)
Current 336 (18.4)
Table II. Surgical characteristics for endarterectomy
Number (%)
Number of carotid endarterectomies 2,127
Symptomatic 770 (36.1)
Laterality – left 1042 (49.4)
Bilateral endarterectomy 670 (31.5)
Intraoperative Shunt 694 (33.0)
Patch 1069 (50.2)
Dacron 680 (32.0)
Vein 355 (16.7)of any stroke in those patients in whom restenosis andanatomic failure developed in the follow-up period was
2.1% and 0.9%, respectively, compared with 3.5% for those
patients without recurrent disease.
Univariate analysis (Table IV) of the variables poten-
tially associated with early restenosis identified elevated
creatinine, residual stenosis, and cholesterol as contributing
and lipid-lowering drugs and carotid patching as protec-
tive. Only lipid-lowering drugs and carotid patching re-
mained significant variables in early anatomic failure. Dur-
ing the late follow-up period, only lipid-lowering drugs
were identified as significantly protective for the progres-
sion of recurrent stenosis or the development of late ana-
tomic failure.
Multivariate models were constructed using reported
Fig 1. Kaplan-Meier curve demonstrating anatomic durability of
carotid endarterectomy versus time. Failure is defined as patients
developing severe restenosis (70% to 99%) or occlusion. The
standard error was always 10%.
Table III. Perioperative complications for
endarterectomies
Complications Number (%)
Total cases 2,127
Stroke or death 30 (1.4)
Cranial nerve injury 9 (0.4)
Transient ischemic attack 6 (0.3)
Bleeding 35 (1.6)
Cardiac 13 (0.6)
Pulmonary 8 (0.4)
Infectious 6 (0.3)
Miscellaneous 11 (0.5)
Total 117 (5.5)risk factors and the significant results of the univariate
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the emergence of female gender as a contributor to early
restenosis (Table V) and elevated cholesterol as a contrib-
utor to late anatomic failure (Table VI). Lipid-lowering
drugs retained a robustly protective effect throughout the
analysis (Tables V and VI) and their administration signif-
Table IV. Univariate analysis for early restenosis, early fail
Early restenosis E
Odds
ratio P
Odds
ratio
Clinical variables
Complication 1.453 .27 2.173
Age (decade) 0.996 .96 0.927
Female 1.277 .12 1.127
Hypertension 1.423 .098 1.162
Diabetes Mellitus 1.107 .58 0.591
COPD 0.896 .65 1.141
Tobacco 0.982 .87 0.799
Coronary artery disease 1.118 .49 0.864
Creatinine (mg/dL) 1.317 .016* 0.843
Development of stroke 0.895 .75 0.002
Surgical variables
Bilateral carotid surgery 0.873 .47 1.007
Symptomatic 0.940 .70 0.987
Shunt use 1.066 .70 0.685
Patch: 0.551 .00018‡ 0.447
Dacron vs none 0.673 .025* 0.381
Vein vs none 0.375 .00020‡ 0.597
Residual stenosis 3.068 .033* 1.602
Lipid variables
Cholesterol (mg/dL) 1.034 .050* 1.047
Triglycerides (mg/dL) 1.003 .74 0.999
HDL (mg/dL) 0.0188 .34 1.009
LDL (mg/dL) 0.0876 .16 0.145
Lipid-lowering drugs 0.551 .00031‡ 0.480
Statin class drug 0.619 .0043† 0.466
COPD, Chronic obstructive pulmonary disease; HDL, high-density lipopro
*P  .05.
†P  .01.
‡P  .001.
Table V. Multivariate analysis for early restenosis and
early failure
Variable
Early restenosis Early failure
Odds ratio P Odds ratio P
Age (decade) 0.943 .57 0.779 .099
Female 1.564 .022* 1.349 .35
Tobacco 0.973 .91 0.558 .21
Diabetes mellitus 0.921 .70 0.578 .17
Creatinine (mg/dL) 1.719 .001† 0.976 .95
Patch 0.543 .001† 0.469 .018*
Cholesterol (mg/dL) 1.003 .070 1.004 .097
Lipid-lowering drugs 0.601 .0071† 0.517 .037*
*P  .05.
†P  .01.
‡P  .001.icantly (P  .0001) improved anatomic durability (Fig 2).In this model, surgical patch of CEA retained its protective
effect on restenosis and anatomic failure only in the early
time period.
Further analysis of patch reconstruction and gender
revealed a higher incidence of patch reconstruction in
women (62% vs 43%, P  .0001). However, the patch
late progression and late failure
ailure Late progression Late failure
P
Odds
ratio P
Odds
ratio P
.11 1.815 .24 2.884 .065
.57 0.896 .32 0.897 .44
.66 1.245 .35 1.418 .26
.67 1.905 .065 1.181 .71
.15 0.751 .339 0.755 .49
.74 1.724 .523 0.682 .48
.26 1.146 .422 1.159 .51
.59 1.083 .73 0.798 .47
.57 1.038 .90 0.871 .75
.39 3.731 .48 1.618 .44
.98 1.106 .69 0.971 .93
.96 0.704 .16 0.556 .10
.23 0.732 .23 0.868 .68
.0047† 0.826 .41 0.907 .76
.0074† 0.842 .51 0.924 .82
.17 0.773 .35 0.848 .71
.53 8.333 .10 3.750 .065
.082 1.002 .54 1.001 .68
.98 1.002 .176 1.000 .77
.38 0.999 .58 0.994 .68
.16 0.995 .23 1.002 .77
.011* 0.246 .0001‡ 0.146 .0001‡
.012* 0.280 .0001‡ 0.176 .0001‡
DL, low-density lipoprotein.
Table VI. Multivariate analysis for late progression and
late failure
Variable
Late progression Late failure
Odds ratio P Odds ratio P
Age (decade) 0.783 .075 0.794 .19
Female 1.068 .83 1.071 .87
Tobacco 1.048 .90 1.063 .90
Diabetes 0.938 .85 0.931 .88
Creatinine (mg/dL) 1.605 .31 1.005 .99
Patch 0.745 .34 0.886 .76
Cholesterol (mg/dL) 1.004 .27 1.009 .039*
Lipid lowering drugs 0.202 .00028† 0.128 .00037†
*P  0.05.
†P  0.001.
**P  0.01.ure,
arly f
tein; Lmaterial used for women versus men (vein, 49% vs 51%;
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ders.
Lipid-lowering drugs were stratified into statin drugs,
nonstatin drugs (nicotinic acid, bile sequestrants, fibric acid
derivatives), or their combination, for further analysis into
their effect on restenosis development. Both the statin (P
.002, odds ratio [OR], 0.589) and nonstatin drugs (P 
.03, OR, 0.365) were protective, and their combination
was partially additive but not synergistic (P  .55).
Survival. The mean patient follow-up period was 5.7
years (range, 0.08 to 13.1). A Kaplan-Meyer estimate for
survival of all CEA patients demonstrated a 2-, 5- and 10-
year survival of 88.1% (confidence interval [CI], 86.6% to
89.6%), 71.3% (CI, 69.2% to 73.5%), and 44.9% (CI, 41.9%
to 48.2%). Stratifying patient survival with CEA anatomic
failure correlated early restenosis (Fig 3) with decreased
longevity (P  .046), whereas a lipid-lowering drug regi-
men (Fig 4) increased survival (P  .00001).
DISCUSSION
Multiple studies have verified that CEA is a safe and
effective procedure to prevent stroke. Randomized, pro-
spective studies have provided clinical guidelines for CEA
with the predicate that the morbidity and mortality rate be
less than the natural history of the disease.1-3 In addition to
the often-emphasized perioperative results, the durability
of the CEA reconstruction is intuitively important to avoid
the increased risk of a secondary procedure for a significant
recurrent stenosis.19,20
Despite the reported small—but not negligible—inci-
Fig 2. Kaplan-Meier curve comparing anatomic durability of ca-
rotid endarterectomy between patients treated with a lipid-lower-
ing drug (solid line) versus those without therapy (dotted line) (P
.0001). Failure is defined the development of severe restenosis
(70% to 99%) or occlusion. Data of lipid-lowering drug (standard
error [SE} 0%) without therapy (SE10%) at 110months (72%,
63% to 81% SE).dence of recurrent stenosis after CEA, reoperative surgeryfor recurrent carotid stenosis is infrequent, largely related
to their low incidence and documented benign natural
history.5,8,19 The reported incidence varies considerably,
depending on the definition of the recurrent stenosis, the
method of examination, and the interval time of follow-up.
Early restenosis of any degree was the most prevalent
finding in our study. Similar to some prior reports, we
found female gender to be a significant correlate with early
restenosis, despite a significantly greater number of women
having a patch reconstruction than men.7,21,22 This would
indicate, especially with the protective effect of patch re-
construction on anatomic durability identified in our and
other studies,7,23 that female gender is a very powerful
contributor to the development of early restenosis.
Another clinical variable identified to significantly cor-
relate with early restenosis was elevated serum creatinine.
Although renal failure has been described as a prime con-
tributor to perioperative morbidity and mortality for vas-
cular surgery, including CEA,20,21 its role in contributing
to CEA restenosis has not been previously described. De-
creased creatinine clearance has, however, been recognized
as a poor prognostic factor for clinical outcome and as a
significant correlate to increased incidence of restenosis
after primary coronary angioplasty.24
The protective effect of carotid patch with CEA was
identified in this and previously reported studies.7,23 Many
other variables, including tobacco smoking,13,22 hyperten-
sion,25 diabetes mellitus,11 residual stenosis,10 and coro-
nary artery disease,11 have been purported to contribute to
recurrent stenosis after CEA. These factors were not iden-
Fig 3. Kaplan-Meier curve demonstrating survival in patients de-
veloping restenosis (dotted line) versus those without restenosis
(solid line) (P .046). Data have standard error [SE]10%, until
no stenosis at 153 months (32%, 26% to 39% SE) and stenosis at
104 months (48%, 41% to 57% SE).tified as predictors in our study, and the reasons for this may
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study was low compared with some of those previously
reported. More prevalent use of -blockers,26 which affects
the rate of coronary restenosis, better methods for tight
control of serum glucose in patients with diabetes mellitus,
and an older population, may all contribute to altering the
influence of these clinical variables on CEA anatomic dura-
bility.
Lipid variables had a significant influence in the analysis
of both the early and the late periods after CEA. Despite
prior reports, evaluation of the specific variables in the lipid
profile, such as high-density lipoprotein and low-density
lipoprotein, did not have any affect on recurrent stenosis in
our study.13,22,27 However, serum cholesterol had a signif-
icant impact on the development of early restenosis and late
anatomic failure, which concurs with previous re-
ports.11,25,28
The one variable, which has not been previously re-
ported, that appeared to have the greatest effect to protect
against recurrent stenosis after CEA throughout this study
was the concurrent administration of a lipid-lowering drug.
This effect was identified independently for both statin and
nonstatin drugs.
In our multivariate model, elevated cholesterol was
persistently identified as an independent predictor of CEA
recurrent stenosis, despite the profound effects of lipid-
lowering drugs. This would suggest that in addition to their
known effect on lowering cholesterol, these drugs might
have other relevant properties that might promote the
anatomic durability of the CEA reconstruction. These in-
clude the decrease of the inflammatory response in the
vessel wall, the increase of circulating endothelial progeni-
tor cells, and the promotion of smooth muscle cell apopto-
sis; all of which have been described with the use of statins
and are known to have a role in the restenotic process.29,30
This newly described effect of lipid-lowering drugs on
inhibiting restenosis after CEA adds to the vascular litera-
ture that has described the beneficial use of statins for
improving infrainguinal bypass graft patency31 and reduc-
ing the incidence of major cardiovascular events during a
6-month period after vascular surgery.32
Previous studies have also documented the protective
effects of lipid-lowering drugs in stroke prevention17 and
improving patient survival.5,33 The survival of patients in
our study on lipid-lowering drugs was also longer (56.4% vs
36.5%, P .0001) at 10 years.With this robust survival rate
of patients after CEA, it is clear that the long-term durabil-
ity of this operation is going to be an even more important
parameter for comparison with other forms of therapy.
The recent reported early results from the Stenting and
Angioplasty with Protection in Patients at High Risk for
Endarterectomy (SAPPHIRE) trial, a prospective, ran-
domized study comparing CEA and carotid artery stenting
with the use of cerebral protection in high-risk patients,
indicate equivalent results for these interventions in the
parameters of death, stroke, and myocardial infarction.14 If
these results are sustained in ongoing trials, the long-termanatomic durability of these reconstructions may ultimately
dictate their application.
Comparing the follow-up data for carotid restenosis,
the range for CEA was reported between 0.1% and 7.9%,
with average follow-up periods of 3 to 7 years,5 and the
range for carotid artery stent reconstructions was between
4% and 14%, with average follow up periods of 1 to 2
years.34,35 The major differences of reporting criteria
within and between these groups preclude quantitative
comparisons; however, there are similarities between pre-
dictors, with carotid stenting reporting positive correlates
with female gender, age, residual stenosis, and multiple
stent use. The overlap in some of these risk factors with our
and other reports of recurrent stenosis after CEA raises the
prospect of only qualitative comparisons. However, the
differences in reporting criteria among all the studies pre-
clude any further analysis and again underline the impor-
tance of identifying reporting standards for carotid inter-
ventional procedures.
These data confirm that CEA is a safe and durable
procedure and join a body of literature that emphasizes the
importance of lipid monitoring and control for patients
with atherosclerotic vascular disease. In addition to dem-
onstrating the positive influence of lipid-lowering drugs on
patient longevity after CEA, this study has underlined their
important contribution to the anatomic durability of CEA.
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